Nexviazyme

Chemical Nameavalglucosidase alfa-ngp
Dosage FormInjection (intravenous; 100 mg)
Drug ClassEnzymes
SystemMusculoskeletal
CompanyGenzyme
Approval Year2021

Indication

  • For the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
Last updated on 6/16/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nexviazyme (avalglucosidase alfa-ngp) Prescribing Information.2021Genzyme Corporation Cambridge, MA